Skip Navigation Links
Home
About Us
Science & Technology
Products
Research & Development
News Room
Contact Us

FOR IMMEDIATE RELEASE:

Quincy Bioscience, LLC Qualifies for Tax Credit under Act 255

MADISON, Wisconsin (March 25, 2005)

Governor Jim Doyle today announced that the Department of Commerce (Commerce) has qualified Quincy Bioscience, LLC Inc. for investor tax credits under the new Angel Investor and Venture Fund Tax Credit Programs created by Act 255.

"This gives us quite a boost as we begin our fundraising efforts", said Mark Underwood, COO of Quincy Bioscience. "I believe we have an exciting investment opportunity and we look forward to connecting with the angel investors in the state of Wisconsin".

The Angel Investor and Venture Fund Tax Credit Programs offer Wisconsin income tax credits to angel investors and investors in seed-stage venture capital funds. These programs are designed to increase the supply of both qualified angel investors and investors in qualified venture capital funds. The tax credits are available only for investments made in technology businesses qualified by Commerce.

Quincy Bioscience is seeking equity financing to further develop its therapeutic compound that addresses the imbalance of calcium ions related to the neuronal degeneration seen in diseases such as Alzheimer's, Parkinson's, Huntington's, Amyotrophic Lateral Sclerosis and other related diseases.

For more information, contact Mark Underwood at munderwood@quincybioscience.com or toll-free at 877-677-8652.

Skip Navigation Links
Home
Prevagen.com
Prevagenpro.com
News Room
Contact Us
 


Copyright © 2008 Quincy Bioscience All rights reserved |  Terms of Use